Actuate Therapeutics Set to Present at Major Investment Conference
Actuate Therapeutics, Inc. (NASDAQ: ACTU), recognized for its groundbreaking efforts in fighting tough cancers, is preparing to make a notable appearance at a leading investment conference. This clinical-stage biopharmaceutical company is focused on creating therapies for challenging malignancies, such as pancreatic cancer and Ewing sarcoma, by inhibiting glycogen synthase kinase-3 beta (GSK-3?).
Conference Information
The H.C. Wainwright 26th Annual Global Investment Conference will be held in New York City from September 9 to 11, 2024, where Actuate will present. The company intends to highlight its progress and strategies for developing therapeutic solutions for impactful cancers. Additionally, the management team will be available for one-on-one meetings, providing an opportunity for investors and stakeholders to connect directly.
Presentation Format and Timing
Actuate Therapeutics will deliver its presentation in a corporate format designed to engage investors and industry leaders. On September 10, 2024, at 4:00 PM ET, the company will provide insights into its innovative strategies and the science behind its leading product, elraglusib.
Webcast Information
For those unable to attend in person, the presentation will be live-streamed. After the event, a recorded version will be made available, allowing stakeholders to stay updated on the latest from Actuate Therapeutics.
About Actuate Therapeutics
Actuate is dedicated to developing pioneering therapies that can combat aggressive cancer types. Their lead investigational product, elraglusib, is central to this mission. It acts as a GSK-3 inhibitor, targeting various molecular pathways that contribute to tumor growth and resistance to chemotherapy. Elraglusib aims to boost anti-tumor immunity by inhibiting NF-kB while also managing immune checkpoints and cellular functions.
Investor Relations and Contact Details
If you want to learn more about Actuate or engage with the company, Mike Moyer is the Managing Director at LifeSci Advisors, LLC. He can be contacted directly via email for any inquiries related to investments or company information.
Frequently Asked Questions
What is the focus of Actuate Therapeutics?
Actuate Therapeutics specializes in developing therapies for high-impact, difficult-to-treat cancers, particularly targeting pancreatic cancer and Ewing sarcoma.
When will Actuate present at the H.C. Wainwright Conference?
Actuate is set to present on September 10, 2024, at 4:00 PM ET during the conference.
How can I access the webcast of Actuate's presentation?
The presentation will be available via live webcast, with a recorded version accessible after the event.
What is elraglusib?
Elraglusib is Actuate's lead investigational drug that targets GSK-3, aiming to reduce tumor growth and enhance the immune response.
Who can I contact for investor inquiries regarding Actuate?
For any investor-related questions, you can reach out to Mike Moyer at LifeSci Advisors, LLC.